Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.02.004
Abstract: Chemotherapy combining cyclophosphamide, bortezomib and dexamethasone is widely used in light-chain amyloidosis. The benefit is limited in patients with cardiac amyloidosis mainly because of adverse cardiac events. Retrospective analysis of our cohort showed that 39 patients… read more here.
Keywords: bortezomib dexamethasone; cyclophosphamide bortezomib; light; amyloidosis ... See more keywords
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16
Sign Up to like & getrecommendations! Published in 2024 at "Blood Advances"
DOI: 10.1182/bloodadvances.2023012539
Abstract: Key Point • The addition of daratumumab to the VCD chemotherapy backbone provides deeper hematological responses and improved PFS. read more here.
Keywords: cyclophosphamide bortezomib; dexamethasone transplant; daratumumab cyclophosphamide; ineligible myeloma ... See more keywords